ClearNote Health

ClearNote Health’s technology identifies genomic differences between cancer and healthy cells to detect disease.

ClearNote Health holds an FDA Breakthrough Device designation for its pancreatic cancer test panel.

The Virtuoso epigenomics platform provides insights into disease biology and therapy response through blood-based testing.

ClearNote Health published a cost-effectiveness analysis of its Avantect Pancreatic Cancer test for managing new-onset diabetes.

XXX

ClearNote presented a poster entitled: “Cancer-induced epigenomic changes in circulating immune cells enable breast, colorectal and lung cancer detection.”

ADA took place in Orlando, FL., June 21–24, 2024.

ClearNote Health attended the 2024 American Society of Clinical Oncology conference to showcase its Virtuoso epigenomic platform for drug development.

ClearNote attended with booth (#6).

ClearNote Health seeks professionals with expertise in biology, AI, and data analysis to improve healthcare outcomes.

No posts were found for provided query parameters.

ClearNote Health applies its epigenomic platform to improve long-term cancer survival through a multidisciplinary team.

ClearNote Health is a cancer detection company committed to extending and improving the lives of individuals at risk for high-mortality cancer.

ClearNote Health rebranded from Bluestar Genomics to reflect its focus on patient-centered cancer detection.

The Avantect Pancreatic Cancer Test detects cancer signals from cell-free DNA in blood using ClearNote Health’s CLIA-certified lab.

ClearNote Health accepts inquiries about its technology and products from researchers, clinicians, investors, and media.

The key to managing cancer is early detection. ClearNote Health makes this possible by finding signals of cancer in the blood early

ClearNote Health provides billing support and flexible payment options for its Pancreatic Cancer Signal Detection Test.

ClearNote Health presents new data on its **Avantect® Pancreatic Cancer Test** and **Virtuoso® platform** at the **AACR Conference on Pancreatic Cancer**, focusing on **5hmC signatures** for treatment monitoring. The company will share findings with attendees and engage with its scientific and medical leadership team during the event in San Diego.

Sep 2026ClearNote HealthNews article

ClearNote Health promotes **Kevin Keegan**, its President and COO, to CEO. **Dave Mullarkey**, the current CEO, will remain as a board member and advisor. The transition reflects a shift in executive leadership while retaining key strategic oversight.

Jul 2026ClearNote HealthNews article

ClearNote Health raises **$52 million in Series D funding** to advance its **noninvasive early cancer detection tools**. The company also appoints **Kevin Keegan** as president and COO, reinforcing its leadership to meet rising demand for accessible and accurate screening solutions. ClearNote focuses on improving detection for some of the deadliest cancers through innovative, noninvasive methods.

May 2026ClearNote HealthNews article

ClearNote Health presents multi-cohort validation data for its **Avantect Pancreatic Cancer Test** at the **2026 ASCO Annual Meeting**, demonstrating early detection advancements for pancreatic cancer. The company, focused on improving survival outcomes for high-mortality cancers, will share findings from real-world patient cohorts. The presentation occurs during ASCO’s annual gathering in Chicago, May 29–June 2, 2026.

May 2026ClearNote HealthNews article